Tesamorelin vs ipamorelin is a comparison between two ways of asking the pituitary to release growth hormone, not two interchangeable versions of the same peptide. Tesamorelin is a 44-amino-acid analogue of growth hormone-releasing hormone (GHRH) and acts at the GHRH receptor. Ipamorelin is a five-amino-acid growth hormone secretagogue that activates the ghrelin receptor. Tesamorelin carries phase 3 evidence for a specific HIV-associated condition; ipamorelin has early pharmacology data and one unsuccessful phase 2 efficacy study. That evidence gap should lead the comparison.
Tesamorelin vs ipamorelin at a glance
| Question | Tesamorelin | Ipamorelin |
|---|---|---|
| What is it? | A 44-amino-acid GHRH analogue | A pentapeptide growth hormone secretagogue |
| Main receptor | GHRH receptor | Growth hormone secretagogue receptor, also called the ghrelin receptor |
| Downstream signal | Pituitary GH release, followed by increased IGF-1 | Pituitary GH release, followed by increased IGF-1 |
| Best human evidence | Two phase 3 trials in adults with HIV and excess abdominal fat | Short IV pharmacology studies and one phase 2 postoperative study |
| Labeled injection burden | Egrifta WR is injected subcutaneously once daily | No approved product label defines a schedule |
| Regulatory position | A branded form exists for one narrow indication | No approved drug product contains ipamorelin |
As of August 2026, compounded tesamorelin is not Egrifta WR, an FDA-approved tesamorelin product for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not labeled for general weight management. Promise's tesamorelin and ipamorelin are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. Ipamorelin has not held FDA approval; the FDA's 2024 review found no approved ipamorelin drug product and no clinical effectiveness data for the proposed subcutaneous route.
A licensed provider may still prescribe a compounded formulation when clinically appropriate; that decision belongs to the patient and the prescriber.
The mechanisms start apart and end together
Tesamorelin resembles the GHRH signal made in the hypothalamus. It binds GHRH receptors and prompts the pituitary to release the body's own GH, which then raises IGF-1 downstream. The current label describes the molecule as the 44-amino-acid sequence of human GHRH with a stabilizing hexenoyl group. What tesamorelin does goes deeper into that pathway.
Ipamorelin approaches the same pituitary output through the growth hormone secretagogue receptor, now identified as the ghrelin receptor. Its foundational 1998 characterization paper established that it is a pentapeptide and showed selective GH release in pituitary cells, rats and swine. Those experiments explain the receptor story; they do not establish a patient outcome or a chronic safety profile. The distinction matters when reading broad lists of ipamorelin benefits.
Different receptors do not mean different end products. Both routes ultimately increase GH signaling and can raise IGF-1. Neither is simply another name for injected human growth hormone.
The evidence is not evenly matched
Tesamorelin's evidence base was built around HIV-associated abdominal fat accumulation. A 2010 pooled analysis of two phase 3 trials included 806 adults. At 26 weeks, the estimated treatment effect on visceral adipose tissue was a 15.4% reduction versus placebo. Among participants who continued tesamorelin, the reduction from the original baseline was 17.5% at 52 weeks. These results apply to the population and outcome studied, not to general weight loss or healthy-adult performance.
The clearest ipamorelin human pharmacology study was much smaller and asked a narrower question. In 1999, researchers gave IV ipamorelin to 40 healthy men across five dose levels. The study measured a roughly two-hour terminal half-life and a single episode of GH release. It did not test body composition, recovery, sleep or long-term outcomes.
The later development program targeted postoperative ileus rather than GH support. In a 2014 phase 2 trial, 117 bowel-resection patients were randomized to IV ipamorelin or placebo. Median time to tolerating a solid meal was 25.3 versus 32.6 hours, a difference that did not reach statistical significance (P=0.15). The program did not proceed to an approved product.
Why the two receptor routes get paired
The pairing has a biological rationale: GHRH-receptor and ghrelin-receptor signals can converge on GH release. A small 2001 study in healthy men found that low-dose native ghrelin plus GHRH produced a larger GH response than the sum of either signal alone. That experiment did not use tesamorelin plus ipamorelin and did not measure clinical outcomes.
This is the line between rationale and evidence. Some prescribers discuss a pair to engage both signaling routes, but the older class experiment cannot establish that the exact compounded combination improves body composition or other outcomes. The dedicated guide to tesamorelin and ipamorelin together covers the combination without turning a receptor hypothesis into a result.
Side effects and injection burden
Tesamorelin has the more complete adverse-event record because hundreds of people received it in phase 3 trials. The current Egrifta WR label lists arthralgia, injection-site redness or itching, pain in the extremities, peripheral edema and myalgia among reactions reported in more than 5% of treated participants. It also calls for attention to elevated IGF-1 and glucose intolerance. Active malignancy, disruption of the hypothalamic-pituitary axis, hypersensitivity and pregnancy are labeled contraindications.
Ipamorelin does not have a comparable chronic subcutaneous data set. In the short postoperative IV trial, treatment-emergent events were reported in 87.5% of the ipamorelin group and 94.8% of the placebo group, but recently operated hospital patients are a poor stand-in for people considering outpatient compounded injections. FDA's review also noted serious events in that study and said their relationship to ipamorelin was unclear. A short trial in a surgical setting cannot supply reliable long-term event rates.
Injection burden is clearer for the branded tesamorelin formulation: its label specifies one subcutaneous injection each day. Ipamorelin has no approved label from which to make a universal comparison. For a compounded formulation, concentration, frequency, monitoring and whether another peptide shares the vial are prescription-specific rather than properties that can be inferred from the compound's name.
How a prescriber separates the requests
For HIV-associated lipodystrophy, tesamorelin has direct phase 3 evidence and a branded product with that indication. For a general body-composition or wellness goal, those trial results are not directly transferable, and ipamorelin does not fill the gap with equivalent outcome data. A comparison with tesamorelin versus sermorelin can help clarify the separate GHRH-analogue question.
A provider also looks at pituitary history, active or prior malignancy, glucose control, pregnancy status, current medications and whether IGF-1 can be monitored. At Promise, a licensed provider reviews every request, and not everyone qualifies; the provider prescribes only when the history, medication list, goals and monitoring plan make a compounded option appropriate.
The useful question is evidence fit
The cleanest choice is not which peptide sounds stronger. It is which evidence matches the reason for considering treatment, and what remains uncertain for that person. Tesamorelin has the heavier clinical record but for a narrow population. Ipamorelin offers a distinct receptor mechanism with much thinner human outcome data. A clinical review should preserve that difference rather than flatten it into a peptide ranking.